The Clinical Usefulness of the PANOMEN 3 Grade Score

Study identification

• EU PAS number:
  EUPAS1000000488
• Study ID:
  1000000488
• Official title and acronym:
  The Clinical Usefulness of the PANOMEN 3 Grade Score
• DARWIN EU® study:
  No
• Study countries:
  Belgium

  Bulgaria

  Denmark

  European Union

  Finland

  France

  Germany

  Greece

  Italy

  Netherlands

  Romania

  Spain

  Sweden
• Study description:
  The second Pituitary Neoplasm Nomenclature workshop (PANOMEN 2), initiated by the Pituitary Society, addressed the need for a comprehensive classification system that could guide prognosis and therapy of all pituitary adenomas (Ho et al. 2023) The PANOMEN 3 clinical classification Workshop has proposed an all-inclusive classification system by integrating clinical, genetic, biochemical, radiological, pathological, and molecular data (Ho et al. 2024). Evidence-based risk factors that are associated with increased morbidity and mortality were included in the classification. A corrected score is calculated dependent on the amount of risk factors assessed and converted into a ranked grade of 0 to 3. These rank grades are hypothesized to be able to reflect disease severity together with a morbidity and mortality risk range. Until now, this classification system has not been applied to a cohort of patients with pituitary adenomas, also not during the stage of conceptualization. Therefore, the discriminative potential together with the clinical usefulness of the system is yet unknown.; ; The primary aim is to evaluate the clinical usefulness of the PANOMEN 3 Grade score in patients with all types of pituitary adenomas seen at Endo-ERN Reference Centers.
• Study status:
  Planned

Research institutions and networks

Institutions

Amsterdam UMC

Networks

European Reference Network on Rare Endocrine Conditions (endo-ERN)

Study timelines

Date when funding contract was signed

Planned:01/10/2023

Study start date

Planned:14/10/2024

Date of final study report

Planned:01/03/2027

Sources of funding

EU institutional research programme

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable